Incyte Corporation
SPIROCYCLIC LACTAMS AS JAK2 V617F INHIBITORS
Last updated:
Abstract:
The present application provides spirocyclic lactam compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
Status:
Application
Type:
Utility
Filling date:
24 Feb 2022
Issue date:
8 Sep 2022